Pyxis Oncology, Inc.
Pyxis Oncology, Inc. (Nasdaq: PYXS) is a clinical-stage oncology company focused on developing novel antibody-drug conjugates to address unmet medical needs in patients with solid tumors. The company's lead product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), represents an investigational ADC that… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Pyxis Oncology, Inc. does
In the company’s own words
Pyxis Oncology, Inc. (Nasdaq: PYXS) is a clinical-stage oncology company focused on developing novel antibody-drug conjugates to address unmet medical needs in patients with solid tumors. The company's lead product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), represents an investigational ADC that uniquely targets extradomain-B fibronectin (EDB+FN), a non-cellular structural component of the tumor microenvironment's extracellular matrix. Unlike conventional ADCs that bind to antigens on cancer cell surfaces, MICVO is designed to bind to EDB+FN in the tumor ECM, where extracellular proteases cleave the linker to release an optimized auristatin payload that directly kills cancer cells, triggers a bystander effect in nearby cells, and stimulates immunogenic cell death.
The company is advancing MICVO through multiple clinical programs, with primary focus on recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC), where preliminary Phase 1 data has demonstrated a 46 percent confirmed objective response rate in efficacy-evaluable patients at the 5.4 mg/kg dose. MICVO is being evaluated both as a monotherapy in the PYX-201-101 trial and in combination with Merck's KEYTRUDA (pembrolizumab) in the PYX-201-102 trial, with combination data showing a 71 percent confirmed ORR in R/M HNSCC patients.
Pyxis Oncology was founded in 2018 and began operations in 2019 with a mission to address difficult-to-treat cancers. The company leverages its Flexible Antibody Conjugation Technology (FACT) platform, developed by Pfizer under a licensing agreement, to produce highly stable ADCs with predictable drug-to-antibody ratios. The company also maintains the APXiMAB platform for antibody discovery and development. The company's strategy includes building a leading ADC-focused oncology company, successfully developing MICVO for R/M HNSCC where significant unmet need exists, forging strategic alliances to support capital-efficient development, and maximizing value from its intellectual property portfolio. More information is available at www.pyxisoncology.com.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1782223
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Pyxis Oncology, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Pyxis Oncology, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Pyxis Oncology, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Pyxis Oncology, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Pyxis Oncology, Inc.'s last four quarterly filings that the numbers alone won't show?”